title: Novel Therapies on Primary Biliary Cirrhosis.
abstract: All patients with primary biliary cirrhosis (PBC) and abnormal liver biochemistry should be considered for specific therapy. Ursodeoxycholic acid (UDCA) is the only FDA-approved drug for treating PBC. Approximately 40% of patients with PBC respond incompletely to treatment with UDCA, thus having increased risk of death or need for liver transplantation. No second-line therapies for patients with inadequate response to UDCA therapy have been approved. This review provides a current perspective on potential new approaches to treatment in PBC, and highlights some of the challenges we face in evaluating and effectively implementing those treatments.
authors.affiliation: University of Miami Miller School of Medicine, 1500 Northwest, 12th Avenue, Suite 1101, Miami, FL 33136, USA.
authors.forename: Frank
authors.initials: F
authors.lastname: Czul
authors.affiliation: Division of Hepatology, University of Miami Miller School of Medicine, University of Miami, 1500 Northwest, 12th Avenue, Suite 1101, Miami, FL 33136, USA. Electronic address: clevy@med.miami.edu.
authors.forename: Cynthia
authors.initials: C
authors.lastname: Levy
mesh_terms: D000069594:Abatacept / Q000627:therapeutic use; D044966:Anti-Retroviral Agents / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D001629:Bezafibrate / Q000627:therapeutic use; D002635:Chenodeoxycholic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002756:Cholagogues and Choleretics / Q000627:therapeutic use; D011345:Fenofibrate / Q000627:therapeutic use; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007155:Immunologic Factors / Q000627:therapeutic use; D008105:Liver Cirrhosis, Biliary / Q000188:drug therapy* / Q000628:therapy; D045164:Mesenchymal Stem Cell Transplantation; D018160:Receptors, Cytoplasmic and Nuclear / Q000819:agonists; D000069283:Rituximab / Q000627:therapeutic use; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use; D000069549:Ustekinumab / Q000627:therapeutic use; D000099150:Receptor, Farnesoid X-Activated
chemical_list: D000069594:Abatacept; D044966:Anti-Retroviral Agents; D061067:Antibodies, Monoclonal, Humanized; D001629:Bezafibrate; D002635:Chenodeoxycholic Acid; D002756:Cholagogues and Choleretics; D011345:Fenofibrate; D005938:Glucocorticoids; D000960:Hypolipidemic Agents; D007155:Immunologic Factors; D018160:Receptors, Cytoplasmic and Nuclear; D000069283:Rituximab; D014580:Ursodeoxycholic Acid; D000069549:Ustekinumab; D000099150:Receptor, Farnesoid X-Activated; C574193:MDX-1100; C464660:obeticholic acid
keywords: Biochemical response; Biomarkers; Immunomodulation; Novel therapies; Primary biliary cirrhosis; Treatment; Ursodeoxycholic acid